Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)

D. O'Malley; M. Neffa; B. J. Monk; T. Melkadze; A. Kryzhanivska; I. V. Bulat; Tarek Meniawy; I. Bondarenko; W. I. Ortuzar Feliu; M. Ancukiewicz; I. Lugowska

doi:10.1016/j.annonc.2021.08.1167

Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)

D. O'Malley, M. Neffa, B. J. Monk, T. Melkadze, A. Kryzhanivska, I. V. Bulat, Tarek Meniawy, I. Bondarenko, W. I. Ortuzar Feliu, M. Ancukiewicz, I. Lugowska

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	S727-S727
Number of pages	1
Journal	Annals of Oncology
Volume	32
DOIs	https://doi.org/10.1016/j.annonc.2021.08.1167
Publication status	Published - 2021
Event	Congress of the European-Society-for-Medical-Oncology (ESMO) - Duration: 16 Sept 2021 → 21 Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2021.08.1167

Cite this

O'Malley, D., Neffa, M., Monk, B. J., Melkadze, T., Kryzhanivska, A., Bulat, I. V., Meniawy, T., Bondarenko, I., Feliu, W. I. O., Ancukiewicz, M., & Lugowska, I. (2021). Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC). Annals of Oncology, 32, S727-S727. https://doi.org/10.1016/j.annonc.2021.08.1167

@article{59753b254c484e76a26478bc1bdfa639,

title = "Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)",

author = "D. O'Malley and M. Neffa and Monk, {B. J.} and T. Melkadze and A. Kryzhanivska and Bulat, {I. V.} and Tarek Meniawy and I. Bondarenko and Feliu, {W. I. Ortuzar} and M. Ancukiewicz and I. Lugowska",

year = "2021",

doi = "10.1016/j.annonc.2021.08.1167",

language = "English",

volume = "32",

pages = "S727--S727",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 16-09-2021 Through 21-09-2021",

}

O'Malley, D, Neffa, M, Monk, BJ, Melkadze, T, Kryzhanivska, A, Bulat, IV, Meniawy, T, Bondarenko, I, Feliu, WIO, Ancukiewicz, M & Lugowska, I 2021, 'Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)', Annals of Oncology, vol. 32, pp. S727-S727. https://doi.org/10.1016/j.annonc.2021.08.1167

TY - JOUR

T1 - Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4)

T2 - Congress of the European-Society-for-Medical-Oncology (ESMO)

AU - O'Malley, D.

AU - Neffa, M.

AU - Monk, B. J.

AU - Melkadze, T.

AU - Kryzhanivska, A.

AU - Bulat, I. V.

AU - Meniawy, Tarek

AU - Bondarenko, I.

AU - Feliu, W. I. Ortuzar

AU - Ancukiewicz, M.

AU - Lugowska, I.

PY - 2021

Y1 - 2021

U2 - 10.1016/j.annonc.2021.08.1167

DO - 10.1016/j.annonc.2021.08.1167

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 32

SP - S727-S727

JO - Annals of Oncology

JF - Annals of Oncology

Y2 - 16 September 2021 through 21 September 2021

ER -